Osaic Holdings’s Faeth Therapeutics FTH Stock Holding History

Osaic Holdings’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-131	Closed	-$38K	–	7116
2021 Q1	$38K	Buy	+131	New	+$43.8K	﹤0.01%	5071

Other funds holding FTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Formula Growth Montreal, Quebec, Canada $222M AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings's FTH Position: Q2 2021 in Review

Osaic Holdings sold out of Faeth Therapeutics (FTH) in Q2 2021, closing a stake of 131 shares — an estimated $38K sold.

Osaic Holdings first reported a position in FTH in Q1 2021 and held it in 1 quarter. The position peaked at $38K in Q1 2021. 34 funds tracked by Wall St. Rank hold FTH as of Q2 2021.

Osaic Holdings reported no remaining Faeth Therapeutics position as of Q2 2021 after selling out during the quarter.
Osaic Holdings sold 131 Faeth Therapeutics shares in Q2 2021, an estimated $38K.
Osaic Holdings first reported a position in Faeth Therapeutics in Q1 2021 and held it in 1 quarter.
Osaic Holdings's Faeth Therapeutics position peaked at $38K in Q1 2021.
34 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2021.

Based on Osaic Holdings's 13F filing for Q2 2021, filed 2 Aug 2021.